ArticleScientific reports2025
Antimicrobial and anti-biofilm activity of Hypericum brasiliense extract and its fractions on Staphylococcus of canine origin.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Evaluation of Uliginosin B as a Modulator of the Ras Pathway: In Vivo Evidence From Caenorhabditis elegans and In Silico Insights.Chemistry & biodiversity · 2026Article
- Antibacterial and Antibiofilm Activities of Bluestem (International journal of microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
The growing resistance to antimicrobials, partly due to the ability to form biofilms, poses a challenge for developing new antimicrobial agents. This study assessed the antimicrobial and antibiofilm activity of Hypericum brasiliense extract, Japonicin, and Uliginosin-B against clinical isolates of S. pseudintermedius and S. coagulans from dogs. The minimal inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) were determined. In vitro antibiofilm activity was evaluated and showed promising results in young (6 h) and mature (24 h) biofilms. S. pseudintermedius and S. coagulans were highly sensitive to all tested substances. All tested isolates exhibited low MIC and MBC values, particularly for Uliginosin-B. Japonicin demonstrated higher MIC and MBC values. The analysis of antibiofilm activity revealed inhibition of biofilm formation and even disruption of pre-formed biofilms at various concentrations, including sub-inhibitory ones. H. brasiliense and its fractions exhibited antimicrobial and antibiofilm activity, offering promising prospects for treating infections caused by biofilm-forming bacteria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.